Description: Centogene BV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.
Home Page: www.centogene.com
CNTG Technical Analysis
Am Strande 7
Rostock,
18055
Germany
Phone:
49 381 80113 500
Officers
| Name | Title |
|---|---|
| Dr. Andrin Oswald M.D., Ph.D. | Advisor |
| Ms. Kim Stratton | CEO & Member of Management Board |
| Mr. Jose Miguel Coego Rios | Chief Financial Officer |
| Dr. Patrice P. Denefle Ph.D. | Chief Scientific Officer |
| Mr. Florian Vogel Ph.D. | Chief Process Officer |
| Dr. Peter Bauer M.D. | Chief Medical & Genomic Officer |
| Ms. Bettina Goerner | Chief Data Officer |
| Mr. Lennart M. Streibel | Director of Corp. Projects |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5904 |
| Price-to-Sales TTM: | 0.1281 |
| IPO Date: | 2019-11-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 808 |